Lung Cancer
A Phase II, Open Label, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene (WS2202)
- Details
ClinicalTrials.gov ID:
NCT06868485
Diagnosis Type:
NA
USOR Number:
- Address
,
P: